<DOC>
	<DOCNO>NCT01379937</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity prime-boost schedule GSK Biologicals ' influenza vaccine child age 3 17 year .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Prime-boost Schedule GSK Biologicals ' Influenza Vaccine Children</brief_title>
	<detailed_description>In study Influenza vaccine GSK1562902A primary study vaccine Havrix™ administer active comparator co-administered along study vaccine.Therefore , exist relation vaccine administer study . As study carry Philippines , Havrix™ vaccine use active comparator instead saline placebo offer advantage subject .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A male female child 3 17 year age inclusive , time first vaccination . Written inform consent obtain subject 's parent guardian . Assent obtain subject applicable . Good general health establish medical history clinical examination enter study . Comprehension subject 's parent guardian study requirement , ability comprehend comply procedure collection short longterm safety data , express availability require study period , ability willingness attend schedule visit . Parent/LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device ( i.e. , commonuse phone serve multiple room apartment ) . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Child care Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Planned administration vaccine 30 day prior 21 day study vaccine administration . Active participation clinical trial . Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Acute disease and/or fever time enrolment : Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Receipt immunoglobulins and/or blood product within 9 month study enrolment plan administration product study period . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction vaccine component history severe adverse reaction previous influenza vaccine . History seizures progressive neurological disease . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Diagnosed cancer chronic severe disease . Previous administration H5N1 vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>influenza</keyword>
	<keyword>H5N1</keyword>
	<keyword>vaccine</keyword>
	<keyword>child</keyword>
</DOC>